Piramal Pharma Limited Takes 74% of Yapan Bio for ₹76 Crore
Key highlights
- Piramal Pharma completed the ₹76 crore cash purchase on August 18, 2026.
- The additional 40.67% stake lifted Piramal Pharma's ownership in Yapan Bio from 33.33% to 74%.
- Yapan Bio reported FY26 revenue of ₹26.34 crore, compared with ₹54.40 crore in FY25.
- The acquisition involved 1,46,400 Yapan Bio equity shares and made the company a subsidiary.
powered by IRIS

Piramal Pharma Limited completed its ₹76 crore acquisition of an additional 40.67% stake in Yapan Bio Private Limited on August 18, 2026, taking its ownership to 74% and making the Hyderabad-based biologics CDMO its subsidiary. The deal brings Yapan Bio under the company’s Piramal Pharma Solutions business.
Know Piramal Pharma inside out
Results, valuation, peers and who's buying, in one view.
What did Piramal Pharma acquire from Yapan Bio?
Piramal Pharma acquired an additional 40.67% equity stake in Yapan Bio from existing shareholders for an aggregate cash consideration of ₹76 crore. The transaction involved 1,46,400 equity shares with a face value of ₹10 each, according to the company’s stock exchange disclosure.
The acquisition was completed on August 18, 2026, after Piramal Pharma exercised a call option announced on August 10. The company stated that the consideration was paid in cash towards Yapan Bio’s common equity. The transaction had initially been subject to a definitive agreement.
Yapan Bio is a Hyderabad-based contract development and manufacturing organisation, or CDMO, focused on vaccines and biologics. Following the deal, it will continue to operate within Piramal Pharma Solutions, Piramal Pharma’s CDMO arm.
How did Piramal Pharma’s ownership of Yapan Bio change?
Piramal Pharma’s stake in Yapan Bio increased from 33.33% to 74% after the acquisition. The incremental purchase changed Yapan Bio’s status from an associate company to a subsidiary of Piramal Pharma.
Before the transaction, Piramal Pharma accounted for its minority investment in Yapan Bio as an associate. With a 74% holding, Yapan Bio becomes a controlled entity. Its revenue, costs and assets can therefore be consolidated in Piramal Pharma’s financial statements, with the remaining 26% represented as a non-controlling interest.
The remaining stake continues to be outside Piramal Pharma’s ownership. The available disclosures do not specify a valuation for Yapan Bio, a plan to acquire the balance 26%, or further details on a potential future transaction involving the remaining shareholders.
What services does Yapan Bio provide?
Yapan Bio provides development and manufacturing services for vaccines and biologics. Its capabilities include process development, characterisation, and Phase I and Phase II good manufacturing practice, or GMP, manufacturing services.
These activities are part of the large-molecule side of the CDMO industry, where companies support pharmaceutical and biotechnology customers in developing and manufacturing complex biologic products. Piramal Pharma said the acquisition strengthens its integrated biologics CDMO capabilities across vaccines, large-molecule products and antibody-drug conjugate development and GMP manufacturing services.
The acquisition also gives Piramal Pharma direct control over a Hyderabad-based operating platform in this area. For Piramal Pharma Solutions, the transaction adds Yapan Bio’s biologics-focused operations to its existing CDMO structure rather than treating the business solely as an equity investment.
Got a follow-up? Ask IRIS
What financial information has been reported for Yapan Bio?
Yapan Bio reported revenue of ₹26.34 crore for the year ended March 31, 2026, compared with ₹54.40 crore in FY25. The reported FY26 revenue was therefore lower than the preceding year’s figure.
The disclosed transaction information does not provide Yapan Bio’s profit, debt, asset base, order book or customer concentration. It also does not disclose the valuation basis used for the ₹76 crore consideration. These omissions limit a like-for-like assessment of the price paid against the company’s recent financial performance.
How does the acquisition affect Piramal Pharma and investors?
The acquisition gives Piramal Pharma control of Yapan Bio and places the business within Piramal Pharma Solutions. The immediate financial reporting effect is that Yapan Bio is expected to be consolidated as a subsidiary rather than accounted for as an associate investment.
For investors, the reported ₹76 crore cash outflow, the increase in ownership to 74%, and Yapan Bio’s FY26 revenue of ₹26.34 crore are the central disclosed metrics. The company did not provide a standalone outlook for Yapan Bio, projected revenue contribution, expected synergies, or a timeline for acquiring the remaining minority stake.
The deal is relevant to the broader CDMO sector because it expands Piramal Pharma’s presence in biologics, vaccines and large-molecule development services. However, no market-price movement, customer contracts, capacity additions or financial targets linked to this acquisition were disclosed in the available information.
Conclusion
Piramal Pharma’s purchase of a further 40.67% of Yapan Bio for ₹76 crore raises its holding to 74% and converts the Hyderabad biologics CDMO from an associate into a subsidiary. The transaction gives Piramal Pharma Solutions direct control of Yapan Bio’s vaccine and biologics development and GMP manufacturing operations.
Investors will watch for future disclosures on Yapan Bio’s financial contribution after consolidation, its operating performance following FY26 revenue of ₹26.34 crore, and any decision by Piramal Pharma on the remaining 26% minority stake. The company has not announced a plan or timeline for a full acquisition.


